(Q34652472)

3 August 2017

1 reference

title

Lopinavir/ritonavir: a review of its use in the management of HIV infection. (English)

1 reference

3 August 2017

0 references

1 reference

1 reference

2

Greg L Plosker

1 reference

3 August 2017

Vicki Oldfield

1

1 reference

PubMed ID

16827606

3 August 2017

language of work or name

1 reference

1 January 2006

1 reference

3 August 2017

1 reference

3 August 2017

66

1 reference

3 August 2017

9

1 reference

3 August 2017

1275-1299

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200666090-00012

3 August 2017

0 references

cites work

A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.

1 reference

12 December 2020

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen

1 reference

12 December 2020

Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients

1 reference

12 December 2020

Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir

1 reference

12 December 2020

Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.

1 reference

12 December 2020

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine

1 reference

12 December 2020

Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children

1 reference

12 December 2020

Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients

1 reference

12 December 2020

Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection

1 reference

12 December 2020

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).

1 reference

12 December 2020

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

1 reference

12 December 2020

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

1 reference

12 December 2020

Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors

1 reference

12 December 2020

Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.

1 reference

12 December 2020

The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients

1 reference

12 December 2020

Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction

1 reference

12 December 2020

The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients

1 reference

12 December 2020

Lopinavir/ritonavir: a review of its use in the management of HIV infection

1 reference

12 December 2020

Probiotics, soluble fiber, and L-Glutamine (GLN) reduce nelfinavir (NFV)- or lopinavir/ritonavir (LPV/r)-related diarrhea

1 reference

12 December 2020

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

12 December 2020

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

1 reference

12 December 2020

Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates

1 reference

12 December 2020

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

1 reference

12 December 2020

Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.

1 reference

12 December 2020

Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir

1 reference

12 December 2020

Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans

1 reference

12 December 2020

Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients

1 reference

12 December 2020

Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro

1 reference

12 December 2020

Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial

1 reference

12 December 2020

Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.

1 reference

12 December 2020

Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families

1 reference

12 December 2020

Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients

1 reference

12 December 2020

Atazanavir: a review of its use in the management of HIV infection

1 reference

12 December 2020

Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients

1 reference

12 December 2020

ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease

1 reference

12 December 2020

Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance

1 reference

12 December 2020

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study

1 reference

12 December 2020

Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease

1 reference

12 December 2020

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

1 reference

12 December 2020

Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra).

1 reference

12 December 2020

Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir

1 reference

12 December 2020

In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification

1 reference

12 December 2020

European guidelines for the clinical management and treatment of HIV-infected adults in Europe

1 reference

12 December 2020

10.2165/00003495-200666090-00012

Identifiers

DOI

1 reference

PubMed ID

16827606

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

16827606